Skip to main content
. 2019 May;47(5):535–544. doi: 10.1124/dmd.118.085035

Fig. 6.

Fig. 6.

Application of PBPK model to predict pharmacokinetics of a single 50-mg oral dose of dolutegravir from in vitro data. Predicted mean concentration versus time profiles (solid lines) with 95th and 5th percentiles (dashed lines) incorporating in vitro glucuronidation kinetics in a stepwise approach from HLMs (A); HLMs and HIMs (B); and HLMs, HIMs, and HKMs (C), overlaid with observed clinical data (squares) are shown.